Advanced lipoprotein measures and recurrent preterm birth by Thorp, John M. et al.
ADVANCED LIPOPROTEIN MEASURES AND RECURRENT
PRETERM BIRTH
John M. Thorp Jr., M.D., Madeline Murguia Rice, Ph.D., Margaret Harper, M.D., M.Sc., Mark
Klebanoff, MD, MPH, Yoram Sorokin, M.D., Michael W. Varner, M.D., Ronald J. Wapner,
M.D., Steve N. Caritis, M.D., Jay D. Iams, M.D., Alan M. Peaceman, M.D., Brian M. Mercer,
M.D., Anthony Sciscione, D.O., Dwight J. Rouse, M.D., Susan M. Ramin, M.D., Garland B.
Anderson, M.D., and for the Eunice Kennedy Shriver National Institute of Child Health and
Human Development Maternal-Fetal Medicine (MFMU) Units Network*
Departments of Obstetrics and Gynecology of University of North Carolina, Chapel Hill, NC
(J.M.T.); Wake Forest University Health Sciences, Winston-Salem, N.C. (M.H.); Wayne State
University, Detroit, MI (Y.S.); University of Utah Health Sciences Center, Salt Lake City, UT
(M.W.V.); Columbia University, New York, NY (R.J.W.); University of Pittsburgh, Pittsburgh, PA
(S.N.C.); The Ohio State University, Columbus, OH (J.D.I.); Northwestern University, Chicago, IL
(A.M.P.); Case Western Reserve University-MetroHealth Medical Center, Cleveland, OH
(B.M.M.); Drexel University College of Medicine, Philadelphia, PA (A.S.); University of Alabama at
Birmingham, Birmingham, AL (D.J.R.); University of Texas Health Science Center at Houston,
Houston, TX (S.M.R.), University of Texas Medical Center, Galveston, TX (G.B.A); and The
George Washington University Biostatistics Center, Washington, DC (M.M.R.); and the Eunice
Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD
(M.K.)
Abstract
OBJECTIVE—Lipoproteins are associated with atherogenic and inflammatory processes, and
these processes may be related to adverse pregnancy outcomes. We therefore examined whether
variations in lipoprotein particle size and concentration are associated with preterm birth (PTB) <
35 weeks’ gestation.
METHODS—This is a case-control ancillary study to a randomized trial of omega-3 fatty acid
supplementation to prevent recurrent PTB. We measured standard lipids and used nuclear
magnetic resonance (NMR) spectroscopy to characterize 17 lipoprotein particles from plasma
collected at the baseline randomization visit (16–21 weeks gestation) in 128 cases (PTB < 35
weeks’ gestation) and 132 term controls. Logistic regression models controlled for study center,
race/ethnicity, number of prior PTB, smoking and treatment group, as well as total LDL, HDL and
triglyceride concentrations when examining LDLNMR lipoproteins, HDLNMR lipoproteins and
VLDLNMR lipoproteins, respectively.
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RESULTS—Only one of the 17 NMR lipoproteins was associated with recurrent PTB. We
observed an increased odds of recurrent PTB of 1.04 (95% CI= 1.01–1.08; p=0.02) per nanometer
increase in VLDLNMR particle size and an odds ratio of 3.00 (CI= 1.40–6.43; p=0.005) for the 3rd
tertile of VLDLNMR particle size compared with the 1st tertile.
CONCLUSION—In women with prior PTB, variations in mid-pregnancy lipoproteins were not
associated with recurrent PTB overall, however the trend observed with VLDLNMR particle size is
suggestive that PTB may be amenable to lifestyle, nutritional or pharmacologic interventions.
INTRODUCTION
The adaptation of a mother to pregnancy culminates in the mobilization of fatty acids from
maternal fat stores in response to increases in insulin resistance that peaks and plateaus at
mid-gestation (1). Pregnancy-associated insulin resistance is induced by pregnancy
hormones and is associated with higher fasting plasma triglycerides (TG) and lower high
density lipoprotein concentrations (HDL) (2). Perturbations in this response are more
pronounced in obese women (2,3,4), are associated with increases in inflammatory markers
(1,2), and are associated with adverse outcomes in pregnancy, such as gestational diabetes
and preeclampsia (5,6). Moreover, these insulin resistance induced metabolic and
inflammatory changes can enzyme expression in maternal adipose tissue and be associated
with preterm birth (PTB) (6).
Lipoprotein perturbations are causal factors in an array of atherogenic and inflammatory
diseases (7,8). Given that inflammation and vascular compromise are hypothesized as causal
paths culminating in PTB, and that pregnancy profoundly alters lipid metabolism, it is
reasonable to assume that lipoprotein changes might be associated with an increased
likelihood of PTB (9,10). We therefore conducted this investigation to determine whether
lipoprotein particle size and number (concentration) are associated with recurrent PTB using
an advanced lipoprotein measure, nuclear magnetic resonance spectroscopy (NMR), which
allows one to measure lipoprotein particle size and concentration (11).
MATERIALS AND METHODS
The data for this report are from the Eunice Kennedy Shriver National Institute of Child
Health and Human Development Maternal–Fetal Medicine Units (MFMU) Network
randomized clinical trial of omega-3 long chain polyunsaturated fatty acid (LCPUFA)
supplementation to prevent recurrent PTB. The trial was conducted at 13 Network Centers
from January, 2005 to October, 2006 and recruited women who had a history of at least one
previous spontaneous singleton PTB (12). A total of 434 women were randomized to receive
daily supplementation of 1200 mg eicosapentaenoic acid (EPA, 20:5n-3) and 800 mg of
docosahexaenoic acid (DHA, 22:6n-3); while 418 were assigned to matching placebos,
beginning at 160 to 216 weeks’ gestation and continuing until 366 weeks’ gestation or
delivery, whichever occurred first. As part of the trial, all enrolled women also received
weekly injections of 17 alpha-hydroxyprogesterone caproate. Women currently taking fish
oil or omega-3 PUFA supplements were ineligible for the trial; detailed inclusion and
exclusion criteria are reported elsewhere (12). Gestational age at delivery was available for
all 852 participants. The study (NCT00125902 at www.clinicaltrials.gov) was approved by
the IRBs of all participating centers and this secondary analysis was determined to be
exempt from IRB review by the Office of Human Subjects Research by the University of
North Carolina, Chapel Hill NC IRB office. All enrolled women gave written informed
consent for participation in the primary study (12). Eligibility for this secondary analysis
was restricted to participants consenting to the use of their blood for future research on
prematurity and other pregnancy complications.
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The current analysis is a nested case-control study in which patients that delivered ≥37
weeks’ gestation were selected as controls and matched on race/ethnicity and study center in
an approximate 1:1 ratio to cases, defined as delivery before 35 weeks’ gestation.
Gestational age at birth was determined from the sonographically-confirmed gestational age
at randomization and the elapsed time from randomization to delivery.
Blood was collected at the baseline randomization visit (160 to 216 weeks’ gestation), before
dispensing study drug. Subjects were not instructed to fast. Standard lipids were measured
by Lipoprofile using a nuclear magnetic resonance autoanalyzer and included total
cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. We relied on a
commercially available laboratory process (Liposcience®, Raleigh, NC) that uses nuclear
magnetic resonance (NMR) technology to assess each individuals’ lipoprotein particle
concentration and size, including very low density lipoprotein (VLDL), low density
lipoprotein (LDL), and high density lipoprotein (HDL) classes and subclasses (NMR
Lipoprofile test [Registered Trademark]). Nuclear magnetic resonance allows investigators
to forego the high expense and labor-intensive approach of ultracentrifugation and has been
used in over 1,000 clinical trials and cohort studies (13,14). In this study, NMR
spectroscopy was used to characterize particle size (in nanometers) and number
(concentration in particle mol/l) of 17 lipoprotein particles from plasma. Particle size
categorization was done using parameters previously delineated using this technology.
Prior to conducting the multivariable analysis, to determine whether the association between
each lipid biomarker and recurrent PTB <35 weeks’ gestation was linear, we assessed the
lipid biomarkers as continuous variables in a model free manner by applying a local
smoother (LOESS). The patients were ranked by lipid value to create 10 groups. For each
group, the median lipid value was calculated along with the corresponding log(odds) of
recurrent PTB. These points were plotted and fitted with two non-parametric (LOESS)
smoothers with 2 separate bandwidths (0.5 and 1.0) and the linearity in the log(odds) was
assessed. Where there was evidence of non-linearity, and when assessing a lipid biomarker
as a continuous variable in a logistic model, we included both linear and quadratic terms for
the lipoprotein.
The association between the lipid biomarkers and recurrent PTB <35 weeks’ gestation was
assessed using logistic regression, conditional on race/ethnicity (Hispanic, non- Hispanic
Black, non- Hispanic White) and study center and adjusting for treatment group. The
following clinically relevant variables were assessed for confounding: age, number of prior
preterm deliveries (1, 2 or more), smoking status and pre-pregnancy body mass index (kg/
m2). To assess whether the association between NMR lipoproteins and recurrent PTB was
independent of standard lipids, models were also adjusted for LDL, HDL and triglycerides
when examining LDLNMR lipoproteins, HDLNMR lipoproteins and VLDLNMR lipoproteins,
respectively; the collinearity between these variables was first assessed. The lipid
biomarkers were assessed as continuous variables, including a quadratic term when relevant,
and also divided into tertiles based on the distribution of the controls as an alternate
approach to present associations. We also assessed whether the association between the
NMR lipoproteins and recurrent PTB differed between the treatment groups by including
NMR lipoprotein × treatment group interaction terms in the multivariable logistic models.
The Hosmer-Lemeshow test was used to check for model fit. All analyses were two-sided
and a p-value < 0.01 was considered statistically significant.
RESULTS
The characteristics of the study population are shown in Table 1. The women with recurrent
PTB were more likely to have smoked during pregnancy and to have had two or more
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previous PTBs. Table 1 also provides the medians and interquartile ranges for the mid-
pregnancy lipid biomarkers. Multivariable models controlled for race/ethnicity, center,
treatment group, number of prior preterm deliveries and smoking status; LDLNMR
lipoproteins were also adjusted for LDL cholesterol; HDLNMR lipoproteins were also
adjusted for HDL cholesterol; VLDLNMR lipoproteins were also adjusted for triglycerides.
Each multivariable logistic model examining the association between a NMR lipoprotein
and recurrent PTB had good model fit as indicted by the Hosmer-Lemeshow test. None of
the interactions between NMR lipoproteins and treatment group was significant.
LDLNMR lipoproteins
None of the LDLNMR lipoprotein concentrations or particle size was associated with
recurrent PTB (Table 2).
HDLNMR lipoproteins
After adjusting for confounders and standard HDL cholesterol, non-linear trends were
observed for two HDLNMR lipoproteins, total HDLNMR particle concentration and medium
HDLNMR particle concentration (Table 2). An inverted U-shaped trend was observed for
total HDLNMR particle concentration (linear term: β=0.528; SE=0.235; p=0.02, quadratic
term: β=−0.007; SE=0.003; p=0.03 for the odds of recurrent PTB). For medium HDLNMR
particle concentration, an irregularly shaped tend was observed with an increased odds of
2.88 (CI=1.17–7.11; p=0.02) for recurrent PTB in tertile 2 compared with tertile 1. These
trends did not reach statistical significance < 0.01.
VLDLNMR lipoproteins
After adjusting for confounders and standard triglycerides, an association was observed for
VLDLNMR particle size (Table 2). A linear trend was observed, with an increased odds of
recurrent PTB of 1.04 (95% CI= 1.01–1.08; p=0.02) per nanometer increase in VLDLNMR
particle size. When examining tertiles, increased odds of recurrent PTB was observed for the
3rd tertile of VLDLNMR particle size compared with the 1st tertile (OR=3.00; 95% CI= 1.40–
6.43; p=0.005) (Table 2).
DISCUSSION
In this exploratory analysis, variations in mid-pregnancy lipoproteins were not associated
with recurrent PTB overall, however the trend observed with increasing VLDLNMR particle
size and increasing odds of recurrent PTB was suggestive. Most importantly, LDL
concentration appears to have no role in recurrent PTB, unlike the crucial role this
lipoprotein plays in adult cardiovascular disease.
Pregnancy is a profound vascular event with uterine blood flow being increased from <1%
to 10–15% of cardiac output via remodeling of the utero-placental vasculature.
Atherosclerotic-like lesions with cholesterol-laden macrophages in the maternal spiral
arteries have been found in pathologic specimens from pregnancies complicated by PTB,
fetal growth restriction, and preeclampsia (9). If the vascular biology at the utero-placental
interface duplicates that seen in other vascular beds, then LDL and VLDL particles play a
major role in cholesterol transport into the lesions and HDL particles help cholesterol efflux.
Extrapolating further, particle size and number of lipoproteins as detected by NMR may
influence the development and regression of these lesions (15, 16).
VLDL carries the bulk of triglycerides (TG) within the circulations of pregnancy and non-
pregnant women. Larger particles are more TG rich and the concentration of VLDL rises
progressively as pregnancy advances (6). This phenomenon is thought to be due to the
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insulin resistance induced by pregnancy and is critical to create an energy-rich environment
within the maternal circulation to serve the caloric needs of the developing fetus (1). Our
observed trend of increased frequency of recurrent PTB with increasing VLDL particle size
(the larger the particle the greater the magnitude of risk) has heretofore not been described.
HDL plays a crucial role in the transport of lipids out of vessel walls in non-pregnant adults
(15). This lipoprotein increases along with other lipoproteins in pregnancy. The particle is
decreased as insulin resistance worsens (1). The smaller the HDL particle the less effective
that particle is in protecting against cardiovascular disease (15). Conversely, to the case in
cardiovascular epidemiology where HDL levels are inversely proportional to risk of disease,
we observed an inverted U-shaped relationship, albeit non-significant per P<0.01 criterion,
between total HDL particle size and recurrent PTB.
Our findings from this secondary exploratory analysis of a clinical trial can at most suggest
hypothetical pathways for future investigations. All of our case and control patients received
progesterone therapy which could have altered lipid metabolism or influenced the results by
other mechanisms. It does demonstrate that lipid biology in pregnancy is complex and
advances in cardiovascular biology cannot be easily extrapolated to the pathogenesis of poor
pregnancy outcome. Ideally, our study would have been done with fasting samples to avoid
any effects of feeding on triglycerides and the particles that transport triglycerides. Some
recent papers question the utility of fasting in lipid assessments and have concluded that
fasting is not helpful (17,18,19). Additionally, given the number of lipid biomarkers
assessed (seventeen), the association between VLDL particle size and recurrent PTB our
findings may simply reflect a type-1 statistical error. Also we only measured lipoproteins at
mid-pregnancy and earlier or later assessments could provide different results. Given the
many lifestyle, nutritional, and pharmaceutical options available to alter lipid profiles, this
remains an area worthy of more study.
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Table 1
Characteristics of the study population
Cases
(recurrent PTB < 35
weeks)
Controls




Age (years), mean ± SD 26.9 ± 5.5 27.1 ± 5.5 0.80
Race/ethnicity, N (%) 0.82
    Non- Hispanic Black 52 (40.6) 50 (37.9)
    Hispanic 15 (11.7) 14 (10.6)
    Non- Hispanic White 61 (47.7) 68 (51.5)
Pre-pregnancy body mass index (kg/m2), mean ± SD 26.9 ± 7.2 26.4 ± 6.2 0.82
Smokers, N (%) 32 (25.0) 13 (9.9) 0.002
Preeclampsia or gestational hypertension, N (%) 5 (3.9) 4 (3.1) 0.75
Assigned to omega-3 group, N (%) 61 (47.7) 71 (53.8) 0.39
Number of prior preterm deliveries, N (%) 0.001
    1 78 (60.9) 106 (80.3)
    2 or more 50 (39.1) 26 (19.7)
Total cholesterol, mg/dl, median (interquartile range) 203 (181, 229) 212 (186, 238) 0.12
LDL measures
  Standard LDL cholesterol, direct, mg/dl, median (interquartile range) 97 (82, 110) 103 (81, 120) 0.21
  LDLNMR lipoprotein particle concentration, nmol/l, median (interquartile
range)
    Total 1114.5 (897.0, 1401.0) 1154.0 (856.5, 1365.5) 0.89
    Large 636.5 (497.5, 811.5) 684.0 (506.0, 841.0) 0.26
    Medium small 70.0 (6.5, 148.0) 47.0 (9.0, 124.0) 0.57
    Small 376.5 (26.0, 767.5) 285.0 (57.0, 624.5) 0.55
    Very small 309.5 (23.5, 613.5) 212.0 (29.5, 513.5) 0.53
    IDL 46.5 (15.0, 81.0) 46.5 (9.0, 90.5) 0.94
  LDLNMR average particle size, nm, median (interquartile range) 21.9 (21.2, 22.6) 22.1 (21.5, 22.6) 0.34
HDL measures
  Standard HDL, mg/dl, median (interquartile range) 58 (51, 64) 60 (52, 68) 0.11
  HDLNMR lipoprotein particle concentration, µmol/l, median (interquartile
range)
    Total 32.9 (29.9, 36.8) 32.9 (29.9, 36.6) 0.88
    Large 11.8 (9.5, 13.9) 11.6 (10.0, 13.3) 0.93
    Medium 0.1 (0.0, 2.1) 0.0 (0.0, 1.6) 0.16
    Small 19.4 (17.4, 22.3) 20.2 (17.0, 23.0) 0.73
  HDLNMR average particle size, nm, median (interquartile range) 9.8 (9.5, 10.0) 9.8 (9.6, 10.0) 0.23
VLDL measures
  Standard triglycerides, mg/dl 157 (125, 214) 148 (111, 196) 0.17
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Cases
(recurrent PTB < 35
weeks)
Controls
(term birth ≥ 37
weeks)
P-valuea
  VLDLNMR lipoprotein particle concentration, nmol/l
    Total VLDL/chylomicrons 70.1 (53.2, 93.4) 74.4 (47.1, 101.4) 0.79
    Large VLDL/chylomicrons 2.3 (0.6, 4.8) 1.4 (0.5, 3.4) 0.04
    Medium 26.6 (16.2, 38.4) 27.8 (15.1, 39.8) 0.83
    Small 41.2 (28.4, 54.2) 42.4 (26.8, 61.4) 0.39
  VLDLNMR average particle size, nm 50.7 (45.9, 56.9) 47.6 (43.7, 53.1) 0.003
PTB, preterm birth; LDL, low density lipoproteins; NMR, nuclear magnetic resonance; IDL, intermediate density lipoproteins; HDL, high density
lipoproteins; VLDL, very low density lipoproteins.
a
Continuous variables were compared using the Wilcoxon test; categorical variables were compared using the chi-square or Fisher’s exact test
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